UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/700/0.1/17.12.25 | Market Closed - Börse Stuttgart 14:07:56 2024-06-27 EDT | ||
| 1.79 EUR | -1.65% |
|
| Current month | +15.48% | ||
| 1 month | +9.15% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-27 | 1.79 | -1.65% |
| 24-06-26 | 1.82 | +4.00% |
| 24-06-25 | 1.75 | -5.41% |
| 24-06-24 | 1.85 | +8.19% |
| 24-06-21 | 1.71 | -5.00% |
Delayed Quote Börse Stuttgart
Last update June 27, 2024 at 02:07 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HD1H5A |
| ISIN | DE000HD1H5A4 |
| Date issued | 2023-12-28 |
| Strike | 700 $ |
| Maturity | 2025-12-17 (538 Days) |
| Parity | 10 : 1 |
| Emission price | 1.4 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.52 € |
|---|---|
| Lowest since issue | 0.52 € |
| Spread | 0.04 € |
| Spread % | 2.21% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
472.5
USD
Average target price
468.3
USD
Spread / Average Target
-0.90%
- Stock Market
- Warrants
- Warrant
